SHINE Technologies announced recently that it acquired Lantheus’ SPECT business, which includes the SPECT manufacturing facility in Massachusetts and its portfolio of diagnostic radiopharmaceuticals. “The nuclear medicine supply chain needs…
BrainXell Therapeutics announced recently preclinical data demonstrating the efficacy of its neuronal therapy called BXT-110 as a potential disease-modifying treatment for Parkinson’s disease. BrainXell Therapeutics is using induced pluripotent stem…
Promega, alongside several research institutions, announced recently the publication of a new study in Nature Communications, highlighting technological advances that may accelerate breakthroughs in precision medicine. According to a release,…
Cellectar Biosciences announced today a multi-year supply agreement with Ionetix Corporation, a full-service radioisotope manufacturer. According to a release, Ionetix will provide Cellectar with a clinical and commercial-scale supply of…
Exact Sciences is being acquired by Abbott, a global healthcare leader, at a total equity value of approximately $21 billion, the company announced today. “Together with Abbott, we can reach…
BioForward Wisconsin revealed its first Wisconsin Biohealth Investor Portfolio Report at its Wisconsin Biohealth Summit last month, the organization announced recently. According to a release, the publication provides a comprehensive…
The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable endometrial carcinoma who…
Exact Sciences announced today the results from its ALTUS Study, which is the largest prospective trial of a blood test for liver cancer surveillance in the United States, with more…
Elephas Biosciences Corporation raised $40 million in a Series B-2 fundraising round, the company announced today. According to a release, the round included participation from existing investors including Northpond Ventures,…
Invenra and Xcellon Biologics, a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody-drug conjugates (ADCs) and complex biologics, announced today a strategic collaboration to advance the development of…
